Antibody data
- Antibody Data
- Antigen structure
- References [54]
- Comments [0]
- Validations
- Immunocytochemistry [3]
- Immunohistochemistry [1]
- Flow cytometry [1]
- Other assay [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12875 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- EGFR Monoclonal Antibody (528)
- Antibody type
- Monoclonal
- Antigen
- Purifed from natural sources
- Description
- MA5-12875 targets Epidermal Growth Factor Receptor in FACS, IHC and IP applications and shows reactivity with Canine and Human samples. The MA5-12875 immunogen is purified EGFR from A431 cells.
- Reactivity
- Human, Canine
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 528
- Vial size
- 500 µL
- Concentration
- 0.2 mg/mL
- Storage
- 4° C
Submitted references Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
mMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes.
Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands.
Propranolol restricts the mobility of single EGF-receptors on the cell surface before their internalization.
Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays.
A Miniaturized Ligand Binding Assay for EGFR.
Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines.
The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner.
Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.
Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.
Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.
Potential localization of putative stem/progenitor cells in human bulbar conjunctival epithelium.
High speed digital protein interaction analysis using microfluidic single molecule detection system.
An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells.
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.
Nuclear EGFR is required for cisplatin resistance and DNA repair.
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.
EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2.
Intracellular MUC1 peptides inhibit cancer progression.
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
Freud-1/Aki1, a novel PDK1-interacting protein, functions as a scaffold to activate the PDK1/Akt pathway in epidermal growth factor signaling.
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction.
Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation.
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Diacylglycerol kinase delta regulates protein kinase C and epidermal growth factor receptor signaling.
Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling.
Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast.
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.
Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex.
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments.
Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.
Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme.
1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor.
Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture.
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Tyrosine-phosphorylated plakoglobin is associated with desmogleins but not desmoplakin after epidermal growth factor receptor activation.
Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation.
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor.
Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor.
Simon N, Antignani A, Sarnovsky R, Hewitt SM, FitzGerald D
Journal of the National Cancer Institute 2016 Aug;108(8)
Journal of the National Cancer Institute 2016 Aug;108(8)
Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
Hasegawa Y, Takahashi M, Ariki S, Asakawa D, Tajiri M, Wada Y, Yamaguchi Y, Nishitani C, Takamiya R, Saito A, Uehara Y, Hashimoto J, Kurimura Y, Takahashi H, Kuroki Y
Oncogene 2015 Feb 12;34(7):838-45
Oncogene 2015 Feb 12;34(7):838-45
mMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes.
Chou CK, Lee HH, Tsou PH, Chen CT, Hsu JM, Yamaguchi H, Wang YN, Lee HJ, Hsu JL, Lee JF, Kameoka J, Hung MC
Science signaling 2014 Mar 4;7(315):rs1
Science signaling 2014 Mar 4;7(315):rs1
Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands.
Henriksen L, Grandal MV, Knudsen SL, van Deurs B, Grøvdal LM
PloS one 2013;8(3):e58148
PloS one 2013;8(3):e58148
Propranolol restricts the mobility of single EGF-receptors on the cell surface before their internalization.
Otero C, Linke M, Sanchez P, González A, Schaap IA
PloS one 2013;8(12):e83086
PloS one 2013;8(12):e83086
Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays.
Pötz O, Schneiderhan-Marra N, Henzler T, Herget T, Joos TO
Methods in molecular biology (Clifton, N.J.) 2012;795:191-202
Methods in molecular biology (Clifton, N.J.) 2012;795:191-202
A Miniaturized Ligand Binding Assay for EGFR.
Schwenk JM, Poetz O, Zeillinger R, Joos TO
International journal of proteomics 2012;2012:247059
International journal of proteomics 2012;2012:247059
Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines.
Ryu SH, Lee SW, Yang YJ, Song SY, Kim JH, Choi EK, Ahn SD
Lung cancer (Amsterdam, Netherlands) 2012 Sep;77(3):482-7
Lung cancer (Amsterdam, Netherlands) 2012 Sep;77(3):482-7
The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner.
Sak MM, Breen K, Rønning SB, Pedersen NM, Bertelsen V, Stang E, Madshus IH
Carcinogenesis 2012 May;33(5):1031-9
Carcinogenesis 2012 May;33(5):1031-9
Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.
Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, Kontermann RE, Pfizenmaier K
Cell death & disease 2012 Apr 12;3(4):e295
Cell death & disease 2012 Apr 12;3(4):e295
Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.
Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z, Veenstra TD, Qiu Y
The Journal of biological chemistry 2011 Oct 14;286(41):36152-60
The Journal of biological chemistry 2011 Oct 14;286(41):36152-60
Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.
Deb TB, Zuo AH, Wang Y, Barndt RJ, Cheema AK, Sengupta S, Coticchia CM, Johnson MD
American journal of physiology. Cell physiology 2011 May;300(5):C1139-54
American journal of physiology. Cell physiology 2011 May;300(5):C1139-54
Potential localization of putative stem/progenitor cells in human bulbar conjunctival epithelium.
Qi H, Zheng X, Yuan X, Pflugfelder SC, Li DQ
Journal of cellular physiology 2010 Oct;225(1):180-5
Journal of cellular physiology 2010 Oct;225(1):180-5
High speed digital protein interaction analysis using microfluidic single molecule detection system.
Chou CK, Jing N, Yamaguchi H, Tsou PH, Lee HH, Chen CT, Wang YN, Hong S, Su C, Kameoka J, Hung MC
Lab on a chip 2010 Jul 21;10(14):1793-8
Lab on a chip 2010 Jul 21;10(14):1793-8
An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells.
Liu HS, Hsu PY, Lai MD, Chang HY, Ho CL, Cheng HL, Chen HT, Lin YJ, Wu TJ, Tzai TS, Chow NH
Carcinogenesis 2010 Aug;31(8):1456-64
Carcinogenesis 2010 Aug;31(8):1456-64
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.
Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA
Experimental dermatology 2010 Aug;19(8):714-22
Experimental dermatology 2010 Aug;19(8):714-22
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW
Cancer letters 2010 Aug 1;294(1):101-10
Cancer letters 2010 Aug 1;294(1):101-10
EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.
Zhang Y, Su H, Rahimi M, Tochihara R, Tang C
International journal of cancer 2009 Nov 1;125(9):2021-8
International journal of cancer 2009 Nov 1;125(9):2021-8
Nuclear EGFR is required for cisplatin resistance and DNA repair.
Hsu SC, Miller SA, Wang Y, Hung MC
American journal of translational research 2009 Mar 8;1(3):249-58
American journal of translational research 2009 Mar 8;1(3):249-58
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.
Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J
Proceedings of the National Academy of Sciences of the United States of America 2009 Mar 10;106(10):3794-9
Proceedings of the National Academy of Sciences of the United States of America 2009 Mar 10;106(10):3794-9
EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2.
Klessner JL, Desai BV, Amargo EV, Getsios S, Green KJ
Molecular biology of the cell 2009 Jan;20(1):328-37
Molecular biology of the cell 2009 Jan;20(1):328-37
Intracellular MUC1 peptides inhibit cancer progression.
Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Jan 1;15(1):100-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Jan 1;15(1):100-9
LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
Stutz MA, Shattuck DL, Laederich MB, Carraway KL 3rd, Sweeney C
Oncogene 2008 Sep 25;27(43):5741-52
Oncogene 2008 Sep 25;27(43):5741-52
Freud-1/Aki1, a novel PDK1-interacting protein, functions as a scaffold to activate the PDK1/Akt pathway in epidermal growth factor signaling.
Nakamura A, Naito M, Tsuruo T, Fujita N
Molecular and cellular biology 2008 Oct;28(19):5996-6009
Molecular and cellular biology 2008 Oct;28(19):5996-6009
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction.
Rajagopalan V, Zucker IH, Jones JA, Carlson M, Ma YJ
American journal of physiology. Heart and circulatory physiology 2008 Aug;295(2):H543-54
American journal of physiology. Heart and circulatory physiology 2008 Aug;295(2):H543-54
Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation.
Umebayashi K, Stenmark H, Yoshimori T
Molecular biology of the cell 2008 Aug;19(8):3454-62
Molecular biology of the cell 2008 Aug;19(8):3454-62
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Xu W, Soga S, Beebe K, Lee MJ, Kim YS, Trepel J, Neckers L
British journal of cancer 2007 Sep 17;97(6):741-4
British journal of cancer 2007 Sep 17;97(6):741-4
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT
Cancer research 2007 Jun 15;67(12):5779-88
Cancer research 2007 Jun 15;67(12):5779-88
Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.
Faivre EJ, Lange CA
Molecular and cellular biology 2007 Jan;27(2):466-80
Molecular and cellular biology 2007 Jan;27(2):466-80
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT
Molecular cancer therapeutics 2007 Aug;6(8):2168-77
Molecular cancer therapeutics 2007 Aug;6(8):2168-77
Diacylglycerol kinase delta regulates protein kinase C and epidermal growth factor receptor signaling.
Crotty T, Cai J, Sakane F, Taketomi A, Prescott SM, Topham MK
Proceedings of the National Academy of Sciences of the United States of America 2006 Oct 17;103(42):15485-90
Proceedings of the National Academy of Sciences of the United States of America 2006 Oct 17;103(42):15485-90
Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling.
Martin NP, Mohney RP, Dunn S, Das M, Scappini E, O'Bryan JP
Molecular pharmacology 2006 Nov;70(5):1643-53
Molecular pharmacology 2006 Nov;70(5):1643-53
Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast.
Kim YS, Bhandari R, Cochran JR, Kuriyan J, Wittrup KD
Proteins 2006 Mar 1;62(4):1026-35
Proteins 2006 Mar 1;62(4):1026-35
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
Funes M, Miller JK, Lai C, Carraway KL 3rd, Sweeney C
The Journal of biological chemistry 2006 Jul 14;281(28):19310-9
The Journal of biological chemistry 2006 Jul 14;281(28):19310-9
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, Koike M, Fujiwara M, Nakao A, Tatematsu M, Nakanishi H
British journal of cancer 2006 Dec 4;95(11):1504-13
British journal of cancer 2006 Dec 4;95(11):1504-13
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.
Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC
Journal of cellular biochemistry 2006 Aug 15;98(6):1570-83
Journal of cellular biochemistry 2006 Aug 15;98(6):1570-83
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL
Oncogene 2005 Sep 15;24(41):6213-21
Oncogene 2005 Sep 15;24(41):6213-21
Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, Walker F, Johns TG, Beth AH, Staros JV
Biochemistry 2005 Nov 15;44(45):14920-31
Biochemistry 2005 Nov 15;44(45):14920-31
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L
Nature structural & molecular biology 2005 Feb;12(2):120-6
Nature structural & molecular biology 2005 Feb;12(2):120-6
Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.
Fan YX, Wong L, Deb TB, Johnson GR
The Journal of biological chemistry 2004 Sep 10;279(37):38143-50
The Journal of biological chemistry 2004 Sep 10;279(37):38143-50
Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex.
Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I, Bögler O
Molecular and cellular biology 2004 Oct;24(20):8981-93
Molecular and cellular biology 2004 Oct;24(20):8981-93
Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments.
Cochran JR, Kim YS, Olsen MJ, Bhandari R, Wittrup KD
Journal of immunological methods 2004 Apr;287(1-2):147-58
Journal of immunological methods 2004 Apr;287(1-2):147-58
Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.
Schmidt MHH, Furnari FB, Cavenee WK, Bögler O
Proceedings of the National Academy of Sciences of the United States of America 2003 May 27;100(11):6505-10
Proceedings of the National Academy of Sciences of the United States of America 2003 May 27;100(11):6505-10
Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme.
Luo X, Gong X, Tang CK
International journal of cancer 2003 May 10;104(6):716-21
International journal of cancer 2003 May 10;104(6):716-21
1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor.
Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A
The Journal of biological chemistry 2002 Oct 11;277(41):38965-71
The Journal of biological chemistry 2002 Oct 11;277(41):38965-71
Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture.
Stoll SW, Kansra S, Elder JT
The Journal of biological chemistry 2002 Jul 26;277(30):26839-45
The Journal of biological chemistry 2002 Jul 26;277(30):26839-45
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Journal of the National Cancer Institute 2001 Sep 19;93(18):1375-84
Tyrosine-phosphorylated plakoglobin is associated with desmogleins but not desmoplakin after epidermal growth factor receptor activation.
Gaudry CA, Palka HL, Dusek RL, Huen AC, Khandekar MJ, Hudson LG, Green KJ
The Journal of biological chemistry 2001 Jul 6;276(27):24871-80
The Journal of biological chemistry 2001 Jul 6;276(27):24871-80
Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME
Cancer research 2000 Jun 1;60(11):3081-7
Cancer research 2000 Jun 1;60(11):3081-7
Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation.
Tikhomirov O, Carpenter G
The Journal of biological chemistry 2000 Aug 25;275(34):26625-31
The Journal of biological chemistry 2000 Aug 25;275(34):26625-31
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME
Cancer research 1999 Oct 15;59(20):5315-22
Cancer research 1999 Oct 15;59(20):5315-22
Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor.
Kiyokawa N, Lee EK, Karunagaran D, Lin SY, Hung MC
The Journal of biological chemistry 1997 Jul 25;272(30):18656-65
The Journal of biological chemistry 1997 Jul 25;272(30):18656-65
Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor.
Kiyokawa N, Lee EK, Karunagaran D, Lin SY, Hung MC
The Journal of biological chemistry 1997 Jul 25;272(30):18656-65
The Journal of biological chemistry 1997 Jul 25;272(30):18656-65
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was done on 90% confluent log phase A431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled EGFR (528) Mouse Monoclonal Antibody (Product # MA5-12875) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing cytoplasmic localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was performed using 90% confluent log phase A-431 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with EGFR Mouse monoclonal antibody (Product # MA5-12875) at 5 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membranous localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of EGFR was performed using 70% confluent log phase A-431 cells (WIld type, panels a,d), CAS9 control (panels b,e) and EGFR Knockout (panels c,f). The cells were fixed, permeabilized, and labelled with EGFR Mouse Monoclonal Antibody(Product # MA5-12875, 5 µg/mL), followed by Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175, 1:2000). Nuclei (blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938) and Rhodamine Phalloidin (Product # R415, 1:300) was used for cytoskeletal F-actin (red) staining. Loss of signal was observed in EGFR Knockout cells (panel c,f) confirming specificity of the antibody to EGFR(green). The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry was performed on formalin-fixed, paraffin-embedded normal canine skin sections. Following antigen retrieval for 20 minutes at 95C in citrate buffer (pH 6), tissues were blocked, and probed with an EGFR monoclonal antibody (Product # MA5-12875) at a dilution of 1:200 for two hours at room temperature, and then overnight at 4C. Tissues were washed extensively with 1X TBS, and detection was performed using an anti-mouse/HRP detection system for 25 minutes at room temperature, followed by DAB substrate for five minutes at room temperature. Tissues were counterstained with hematoxylin and visualized at 40X magnification using a light microscope. Data courtesy of the Innovators Program.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of EGFR was done on A-431 cells. Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with EGFR Mouse Monoclonal Antibody (MA512875, red histogram) or with mouse isotype control (yellow histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Rabbit Anti-Mouse Secondary Antibody (A11059) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of Epidermal Growth Factor Receptor using Epidermal Growth Factor Receptor Monoclonal Antibody (Product # MA5-12875) on Native Human A431 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of Epidermal Growth Factor Receptor using Epidermal Growth Factor Receptor Monoclonal Antibody (Product # MA5-12875) on Native Human A431 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of Epidermal Growth Factor Receptor using Epidermal Growth Factor Receptor Monoclonal Antibody (Product # MA5-12875) on Native Human A431 Cells.